The Pharma Data

JUNE 18, 2021

June 8, 2021 /PRNewswire/ — Allergan Aesthetics, an AbbVie company (NYSE: ABBV ), is changing the way BOTOX ® Cosmetic, the #1 selling neurotoxin treatment 1 , is connecting with consumers. IRVINE, Calif. Experience the interactive Multimedia News Release here: [link] . Each story is unique. Each story is unique.

Doctors 52

Doctors FDA Approval Production Treatment 52

The Pharma Data

FEBRUARY 13, 2022

Current treatment options in this age group are primarily topical steroids, which can be associated with safety risks and may impair growth when used long-term. In 2016, the FDA granted Breakthrough Therapy designation for Dupixent for the treatment of severe atopic dermatitis (in children aged 6 months to 11 years).

FDA 40

FDA Disease Treatment FDA Approval 40

Agency IQ

JUNE 17, 2024

As reported by POLITICO , “The decision — if allowed by the Supreme Court to take effect — would roll back actions the federal government has taken since 2016 to make the pills more accessible, including rules allowing online ordering, mail delivery, and pharmacy dispensing of the drugs. Read AgencyIQ’s analysis of that case here. ]

FDA 40

FDA Doctors Testimonials Regulations 40

FDA Law Blog: Biosimilars

FEBRUARY 26, 2024

Relevant here, FDA interpreted in Guidance that a proposed injectable biosimilar must “demonstrate that its product has the same strength as the reference product by demonstrating that both products have the same total content of drug substance (in mass or units of activity) and the same concentration of drug substance.”

FDA 59

FDA Biosimilars Production Regulations 59

Metabolite Tales Blog

JANUARY 23, 2024

Metabolism of 2023 FDA Approved Small Molecules – PART 1 By Julia Shanu-Wilson 2023 was a fruitful year for drug approvals by the FDA, with a crop of 34 small molecules out of a total of 55 new drugs [1]. link] [3] FDA prescribing information for daprodustat. Basic Clin Pharmacol Toxicol. 131(5): 311- 324.

Small Molecule 52

Small Molecule FDA Approval FDA Pharmacokinetics 52

Dark Matter Blog

AUGUST 27, 2020

In early August, risdiplam, an orally available small molecule that binds to a stem-loop structure in the SMN2 pre-mRNA, received FDA approval for the treatment of spinal muscular atrophy , a devastating genetic disease. At the time of that publication risdiplam was also in clinical trials for the treatment of SMA patients.

Small Molecule 52

Small Molecule RNA Clinical Trials Drugs 52

NIH Director's Blog: Drug Development

JULY 20, 2017

Credit: Zhang & Chen, 2016, Cell 167, 1586–1597. Specifically, after 2 to 4 weeks of treatment with this combination of two correctors and a potentiator, such patients experienced about a 10 percentage point improvement in forced expiratory volume in 1 second (FEV1), which is a key measure of lung capacity.

Clinical Trials 52

Clinical Trials Small Molecule Disease Therapies 52

NIH Director's Blog: Drug Development

JUNE 14, 2016

Scott and colleagues focused on six genes that encode potential drug targets licensed or in development by GlaxoSmithKline for the treatment of obesity or diabetes. That’s critical considering that just 1 in 10 drug candidates entering human clinical trials successfully goes on to receive FDA approval [5]. 2016 March 4. [5]

Drugs 52

Drugs Disease Drug Development Clinical Trials 52

FDA Law Blog: Biosimilars

JANUARY 18, 2024

FDA conducted the eight-factor scheduling analysis required by the CSA in 2016 and found that marijuana continued to meet the scheduling criteria for remaining in schedule I. 12, 2016); Denial of Petition to Initiate Proceedings to Reschedule Marijuana, 81 Fed. 53,688 (Aug. 53,767 (Aug. 21 U.S.C. §

FDA 69

FDA FDA Approval Treatment Drugs 69

The Pharma Data

JANUARY 11, 2021

based subsidiary of Terumo and a global neurovascular company, announced today the FDA Approval of the PMA Supplement for the WEB 17 System, a new addition to the WEB Aneurysm Embolization System for the treatment of intracranial wide neck bifurcation aneurysms. The WEB System received its first PMA approval in late 2018.

FDA Approval 52

FDA Approval Treatment FDA Therapies 52

The Pharma Data

JUNE 18, 2021

Food and Drug Administration (FDA) has approved PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine) for the prevention of invasive disease and pneumonia caused by the 20 Streptococcus pneumoniae (pneumococcus) serotypes in the vaccine in adults ages 18 years and older. Following today’s FDA approval, the U.S.

Vaccine 52

Vaccine FDA Approval FDA Disease 52

FDA Law Blog: Biosimilars

AUGUST 8, 2024

Rescheduling out of schedule I would allow for the medical use of FDA-approved prescription drugs dispensed by DEA-registered, state licensed pharmacies pursuant to prescriptions issued by similarly DEA-registered, state licensed practitioners. 12, 2016); Denial of Petition To Initiate Proceedings to Reschedule Marijuana, 81 Fed.

Regulations 59

Regulations Pharmacy Licensing Licensing 59

Drug Discovery World

AUGUST 10, 2022

Until about 25 years ago, the best treatment option for someone with blood cancer was either toxic radiation and chemotherapy or a bone marrow transplant that posed additional life-threatening risks to the patient 1. Next, the advent of antibody treatments in 1997 created the first targeted cancer therapy 2.

Therapies 246

Therapies Virus Treatment Engineering 246

Agency IQ

SEPTEMBER 15, 2023

Until recently, the FDA relied on a monograph process through which firms could bring OTC drugs to market without FDA approval so long as it adhered to pre-set terms under the monograph. The FDA will follow these procedures for both agency-initiated operations (e.g.,

Science 40

Science FDA Clinical Trials Pharmacy 40

The Pharma Data

SEPTEMBER 15, 2020

Next-generation biomarker cytology test supports World Health Organization’s goal to eliminate cervical cancer, which is nearly 100 percent preventable with proper screening, vaccination and treatment. Basel, 16 September 2020 — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Publication of the full IMPACT study findings is pending.

FDA Approval 52

FDA Approval FDA Laboratories Disease 52

The Pharma Data

DECEMBER 21, 2020

21 December 2020 — AstraZeneca’s Tagrisso ( osimertinib ) has been approved in the US for the adjuvant treatment of adult patients with early-stage epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after tumour resection with curative intent. 0.23; p<0.0001).

Treatment 52

Treatment Trials Disease FDA 52

Drug Target Review

JUNE 21, 2023

4 For the treatment of rare genetic disorders especially, drugs with genetically supported targets are more than twice as likely to be approved 5 , thereby indicating genetics and genomics can empower companies to develop better drugs. Human genetics evidence supports two-thirds of the 2021 FDA-approved drugs.

Disease 111

Disease Clinical Trials Therapies Science 111

Drug Discovery World

APRIL 17, 2023

Cancer Moonshot In 2016, when Joe Biden was the US Vice President, he led the Cancer Moonshot initiative with the mission to accelerate the rate of progress against cancer. She said it is not always feasible to offer treatment that will permit the mother to live long enough for the pregnancy to reach viability. Read more here.

Research 130

Research FDA Approval Therapies Treatment 130

The Pharma Data

AUGUST 30, 2021

Results reinforce well-established safety profile of Dupixent – the first ever biologic medicine for atopic dermatitis currently approved for patients as young 6 years old. Parents and caregivers are challenged to find safe and effective treatment options,” said John Reed, M.D., In 2016, the U.S.

Trials 52

Trials Disease Treatment Clinical Trials 52

The Pharma Data

JUNE 28, 2021

Food and Drug Administration (FDA) for the use of the oral anticoagulant Xarelto (rivaroxaban) in pediatric patients. There are currently no FDA-approved anticoagulation therapies for pediatric patients with congenital heart disease who have undergone the Fontan procedure. EINSTEIN-Jr.

FDA 52

FDA Clinical Trials Treatment Therapies 52

The Pharma Data

JUNE 18, 2021

Additionally, new data will be presented during the European Hematology Association (EHA) Virtual Congress from June 9-17 , including findings from the informCLL real-world prospective observational registry assessing how real-world treatment patterns align with National Comprehensive Cancer Network (NCCN ® )-recommended regimens for CLL/SLL.

FDA Approval 40

FDA Approval Treatment FDA Therapies 40

The Pharma Data

JUNE 26, 2021

Food and Drug Administration (FDA) for the use of XARELTO ® (rivaroxaban) in pediatric patients. If approved, XARELTO ® will be the first and only oral Factor Xa inhibitor indicated in the U.S. EINSTEIN-Jr is the largest pediatric study completed to date for the treatment of VTE. for use in pediatric patients.

Doctors 52

Doctors Hospitals Clinical Trials Treatment 52

The Pharma Data

DECEMBER 15, 2020

Treatment induced sustainable clinical responses and reduced systemic inflammation. Daratumumab already is approved for the treatment of multiple myeloma. The company is developing its platform for the treatment of chronic, inflammation-mediated autoimmune diseases, and is initially focused on the treatment of RA.

Disease 52

Disease Clinical Trials Small Molecule Trials 52

NIH Director's Blog: Drug Discovery

MARCH 8, 2016

The approach might also be put to use for optimizing drug candidates or for discovering new uses for cancer drugs that have already been FDA approved. While that remains a tremendous challenge, this new method could help to bring the goal of discovering many more precise and effective cancer treatments within better reach.

DNA 52

DNA Drugs Small Molecule FDA Approval 52

FDA Law Blog: Biosimilars

SEPTEMBER 5, 2023

Houck — Scheduling Criteria Under the Controlled Substances Act (“CSA”) Schedule I: • High potential for abuse; • No currently accepted medical use in treatment in the U.S.; Schedule III: • Potential for abuse less than drugs or substances in schedules I and II; • Currently accepted medical use in treatment in the U.S.; 21 U.S.C. §

FDA 111

FDA Treatment FDA Approval Drugs 111

FDA Law Blog: Biosimilars

MAY 21, 2024

We wondered how given that HHS and the Drug Enforcement Administration (“DEA”) conducted eight-factor scheduling analyses in 2016, concluding that there was “no substantial evidence that marijuana should be removed from Schedule I.” 12, 2016) ; Denial of Petition to Initiate Proceedings to reschedule Marijuana, 81 Fed. 12, 2016).

Regulations 69

Regulations FDA Licensing Licensing 69

Agency IQ

DECEMBER 1, 2023

12/29/2023 FDORA, Section 3202 Orphan Drug Program : FDA will convene a public meeting (or several) to solicit input from stakeholders regarding rare disease patient burdens, treatment options, side effects of treatments, etc.

FDA 40

FDA Science Regulations Production 40

Agency IQ

OCTOBER 27, 2023

Title Type Date Cleared by OIRA Legal Deadline None Notable FDA Comment Periods Closing in November and December FDA comment periods are typically open for 30-60 days, unless they are extended. Within 180 days, FDA will release a report on the proceedings of the public meeting and any recommendations.

FDA 40

FDA Science Regulations Production 40

Codon

JUNE 18, 2024

. ” However, studies over the last six decades have repeatedly affirmed that ultrasound is safe , at least when used in the short durations common to medical imaging and treatment. At least six types of CAR-T cells have already passed through clinical trials and garnered FDA approval.

Engineering 66

Engineering Laboratories International Clinical Trials 66

The Pharma Data

SEPTEMBER 10, 2021

If approved for this indication, we believe MYFEMBREE has the potential to redefine care for women with endometriosis as an effective, one pill, once-a-day treatment option.”. We look forward to potentially bringing this important new treatment option to women with endometriosis.”. In the U.S., About MYFEMBREE®.

FDA Approval 52

FDA Approval Treatment Therapies Science 52

The Pharma Data

OCTOBER 14, 2020

Food and Drug Administration (FDA) approved Inmazeb, a three-antibody cocktail to treat Ebola infections in adults and children. It has also been approved for newborns of mothers who have tested positive for Ebola. during the 2014 to 2016 epidemic. In 2019, the FDA approved an Ebola vaccine, Merck’s Ervebo. “We

FDA 40

FDA Treatment FDA Approval Virus 40

FDA Law Blog: Biosimilars

MAY 5, 2024

Scheduling Under the CSA Substances in schedule I of the CSA have a high potential for abuse, no currently accepted medical use in treatment in the U.S., Those in schedule III have a potential for abuse less than schedule I or II substances, have a currently accepted use in treatment in the U.S., 21 U.S.C. § 21 U.S.C. § 53,688 (Aug.

FDA 95

FDA Regulations Treatment Licensing 95

Drug & Device Law

MAY 19, 2023

The core premise of Bexis’ article is very simple: Once the FDA has said “yes” and approved a particular drug for a particular indication (“intended use”) for sale in the United States, federal preemption precludes any state from saying say “no” and trying to ban that same FDA-approved drug. In GenBioPro, Inc.

FDA Approval 111

FDA Approval Pharmacy FDA Production 111

Drug & Device Law

MAY 11, 2023

Its staff has a broad view tied to public health considerations, available drug and non-drug treatment options, data that may not be publically available, and decades of experience with the subject matter. 330, 339 (2016), and Clapper v. That all matters because judges lack that expertise, broad view, and experience. Brief at 11 n.1.

FDA 59

FDA FDA Approval Research Treatment 59

Drug & Device Law

DECEMBER 29, 2023

The FDA requires real science for warnings; thus it had not mandated any warning remotely resembling Prop 65. The plaintiff failed to identify any method by which a generic (or any other) drug manufacturer could add a Prop 65 warning without deviating from FDA-approved labeling, thereby violating federal law. 13) McGee v.

Testimonials 105

Testimonials FDA Drugs Vaccine 105

Drug & Device Law

OCTOBER 20, 2023

FDA/Alliance for Hippocratic Medicine v. LLC litigation, in which an anti-abortion group is seeking to invalidate regulatory actions taken by the FDA with regard to mifepristone , a pharmaceutical FDA-approved for use in the termination of pregnancy to ten weeks, in combination with misoprostol. Danco Labs.,

FDA 59

FDA FDA Approval Pharmaceuticals Clinical Trials 59

Drug & Device Law

MAY 26, 2022

In Hand , the court tackled a range of issues, but the part that stands out to us is the treatment of the misrepresentation-based claims, even with the court’s unwieldy preemption rulings in the way. The BHR court dug in to an extent many MDL court do not in granting summary judgment in In re BHR (Hand v. Smith & Nephew) , No.

Doctors 59

Doctors FDA FDA Approval Production 59